Last updated: July 17, 2026

Application No. 18/531,312

USE OF IMMUNE CHECKPOINT INHIBITORS IN CENTRAL NERVOUS SYSTEMS NEOPLASMS

Non-Final OA

Filed

Dec 06, 2023

Priority

Dec 16, 2014 — provisional 62/092,783 +5 more

Examiner

MOSELEY II, NELSON B

Art Unit

Tech Center

Assignee

Bristol-Myers Squibb Company

OA Round

1 (Non-Final)

Interview Optional

— +41.2% interview lift. Examiner has a relatively high allowance rate (68%); +41.2% interview lift. A written response may suffice.

Based on 618 resolved cases, 2023–2026

Examiner Intelligence

MOSELEY II, NELSON B View full profile →

Grants 68% — above average

Career Allowance Rate

420 granted / 618 resolved

+8.0% vs TC avg

Strong +41% interview lift

Without

With

+41.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 1m

Avg Prosecution

47 currently pending

Career history

658

Total Applications

across all art units

Statute-Specific Performance

§101

3.4%

-36.6% vs TC avg

§103

41.5%

+1.5% vs TC avg

§102

6.0%

-34.0% vs TC avg

§112

19.8%

-20.2% vs TC avg

Black line = Tech Center average estimate • Based on career data from 618 resolved cases

Prosecution Timeline

Dec 06, 2023

Application Filed

May 27, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/909,578

Patent 12679886

SERUM ALBUMIN BINDING NANOBODY COMPOSITIONS AND METHODS FOR USING THE SAME

3y 10m to grant Granted Jul 14, 2026

17/905,745

Patent 12643954

ANTI-CD36 ANTIBODIES AND THEIR USE TO TREAT CANCER

3y 9m to grant Granted Jun 02, 2026

16/065,488

Patent 12637500

TUMOR ANTIGEN PEPTIDE

7y 5m to grant Granted May 26, 2026

17/958,259

Patent 12630620

ANTI-GDF15 NEUTRALIZING MONOCLONAL ANTIBODY AND USE THEREOF

3y 7m to grant Granted May 19, 2026

18/045,129

Patent 12631641

METHOD OF IDENTIFYING TREATMENT RESPONSIVE NON-SMALL CELL LUNG CANCER USING ANAPLASTIC LYMPHOMA KINASE (ALK) AS A MARKER

3y 7m to grant Granted May 19, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

68%

Grant Probability

99%

With Interview (+41.2%)

3y 1m (~6m remaining)

Median Time to Grant

Low

PTA Risk

Based on 618 resolved cases by this examiner. Grant probability derived from career allowance rate.